AU2005279278A1 - Fused tricyclic derivatives for the treatment of psychotic disorders - Google Patents

Fused tricyclic derivatives for the treatment of psychotic disorders Download PDF

Info

Publication number
AU2005279278A1
AU2005279278A1 AU2005279278A AU2005279278A AU2005279278A1 AU 2005279278 A1 AU2005279278 A1 AU 2005279278A1 AU 2005279278 A AU2005279278 A AU 2005279278A AU 2005279278 A AU2005279278 A AU 2005279278A AU 2005279278 A1 AU2005279278 A1 AU 2005279278A1
Authority
AU
Australia
Prior art keywords
alkyl
alkoxy
methyl
haloc
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005279278A
Other languages
English (en)
Inventor
Jonathan Bentley
Markus Bergauer
Barbara Bertani
Matteo Biagetti
Manuela Borriello
Steven Mark Bromidge
Massimo Gianotti
Enrica Granci
Colin Philip Leslie
Alessandra Pasquarello
Valeria Zucchelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0419315A external-priority patent/GB0419315D0/en
Priority claimed from GB0507386A external-priority patent/GB0507386D0/en
Priority claimed from GB0515010A external-priority patent/GB0515010D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2005279278A1 publication Critical patent/AU2005279278A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2005279278A 2004-08-31 2005-08-29 Fused tricyclic derivatives for the treatment of psychotic disorders Abandoned AU2005279278A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0419315A GB0419315D0 (en) 2004-08-31 2004-08-31 Compounds
GB0419315.7 2004-08-31
GB0507386A GB0507386D0 (en) 2005-04-12 2005-04-12 Compounds
GB0507386.1 2005-04-12
GB0515010A GB0515010D0 (en) 2005-07-21 2005-07-21 Compounds
GB0515010.7 2005-07-21
PCT/EP2005/009379 WO2006024517A1 (en) 2004-08-31 2005-08-29 Fused tricyclic derivatives for the treatment of psychotic disorders

Publications (1)

Publication Number Publication Date
AU2005279278A1 true AU2005279278A1 (en) 2006-03-09

Family

ID=35106764

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005279278A Abandoned AU2005279278A1 (en) 2004-08-31 2005-08-29 Fused tricyclic derivatives for the treatment of psychotic disorders

Country Status (17)

Country Link
US (1) US20120022056A1 (https=)
EP (1) EP1786822A1 (https=)
JP (1) JP2008511574A (https=)
KR (1) KR20070057885A (https=)
CN (1) CN101048414B (https=)
AR (1) AR053307A1 (https=)
AU (1) AU2005279278A1 (https=)
BR (1) BRPI0514377A (https=)
CA (1) CA2578781A1 (https=)
IL (1) IL181387A (https=)
MA (1) MA28871B1 (https=)
MX (1) MX2007002548A (https=)
NO (1) NO20071326L (https=)
NZ (1) NZ553506A (https=)
PE (1) PE20060653A1 (https=)
TW (1) TW200619221A (https=)
WO (1) WO2006024517A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7898642B2 (en) 2004-04-14 2011-03-01 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
JP4324221B2 (ja) * 2005-08-26 2009-09-02 株式会社医薬分子設計研究所 Ｐｐａｒアゴニスト活性を有する誘導体
JP2009523820A (ja) * 2006-01-23 2009-06-25 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼの三環系抑制剤
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
JP2010504367A (ja) 2006-09-26 2010-02-12 グラクソ グループ リミテッド 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体
AU2008223348A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
GB0800840D0 (en) 2008-01-17 2008-02-27 Glaxo Group Ltd Novel salt
DK2268644T3 (da) 2008-03-05 2011-10-10 Boehringer Ingelheim Int Tricycliske pyridinderivater, medikamenter indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
WO2010111626A2 (en) * 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
EA201201160A1 (ru) 2010-02-19 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP5947382B2 (ja) 2011-08-17 2016-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フロ［３，４−ｃ］キノリン誘導体、このような化合物を含む薬物、それらの使用及びそれらの調製方法
EP2792679A1 (en) * 2013-04-19 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Tricyclic triazolic compounds
JP6523267B2 (ja) * 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
IL124914A (en) * 1997-06-26 2000-10-31 Akzo Nobel Nv Pharmaceutical compositions containing 6-aryl-2,3,5,6-tetrahydroimidazo¬2,1-a¾isoquinoline derivatives and some new such compounds
US6919334B2 (en) * 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
US20120022056A1 (en) 2012-01-26
EP1786822A1 (en) 2007-05-23
WO2006024517A1 (en) 2006-03-09
PE20060653A1 (es) 2006-09-27
IL181387A (en) 2011-10-31
KR20070057885A (ko) 2007-06-07
NO20071326L (no) 2007-05-03
CN101048414A (zh) 2007-10-03
MA28871B1 (fr) 2007-09-03
AR053307A1 (es) 2007-05-02
TW200619221A (en) 2006-06-16
CA2578781A1 (en) 2006-03-09
NZ553506A (en) 2010-02-26
IL181387A0 (en) 2007-07-04
BRPI0514377A (pt) 2008-06-24
MX2007002548A (es) 2007-04-24
CN101048414B (zh) 2011-09-07
JP2008511574A (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
IL181387A (en) Fused tricyclic derivatives for the treatment of psychotic disorders
AU2014334554B2 (en) Selectively substituted quinoline compounds
US8097618B2 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
JP5903499B2 (ja) ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
CN104507939B (zh) 四氢吡唑并嘧啶化合物
WO2011012622A1 (en) Benzoxazinone derivatives for the treatment of glytl mediated disorders
US9376436B2 (en) 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators
JP2010519226A (ja) ５−ｈｔ６受容体親和性を有する６’位置換インドール及びインダゾール誘導体
WO2009138393A1 (en) 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
US20100004452A1 (en) 5-quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairment, psychotic disorders, anxiety, depression, etc.
CN102574858B (zh) 双环杂环及其作为ccr2受体拮抗剂的用途
CN105793266A (zh) 螺-噁唑酮
RU2409582C2 (ru) Конденсированные трициклические производные для лечения психотических расстройств
WO2010142652A1 (en) Imidazobenzazepine compounds for the treatment of central nervous system (cns) diseases
HK1197409A (en) 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis
HK1197409B (en) 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis
HK1223922B (zh) 螺-恶唑酮

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted